FIELD: medicine.
SUBSTANCE: invention relates to the use of the compound 2-[3-(2-chloroethyl)-3-nitrosoureido]–1.3-propanediol for the treatment of Ehrlich carcinoma, sarcoma 37, lymphosarcoma LIO-1, melanoma B16, transplanted into the lower eyelid of mice in an experiment at a dose of 15 or 20 mg/kg once intraperitoneally. The claimed use of 2-[3-(2-chloroethyl)-3-nitrosoureido]-1.3-propanediol can achieve 100% inhibition of the growth of eyelid tumors and increase the median life expectancy of animals, respectively, by 84%, > 154%, > 150% and 67%. In mice with sarcoma 37 and LIO-1 lymphosarcoma transplanted under the skin of the lower eyelid, a single administration of 2-[3-(2-chloroethyl)-3-nitrosoureido]-1.3-propanediol at a dose of 20 mg/kg resulted in complete recovery of 89% and 67% of the animals, respectively.
EFFECT: extension of the range of experimental pharmaceuticals.
1 cl, 16 dwg, 8 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
USE OF THE COMPOUND 2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1,3-PROPANEDIOL ORALLY FOR THE TREATMENT OF MELANOMA B16, EHRLICH TUMOR, SARCOMA 180, SARCOMA 37, LYMPHOSARCOMA LIO-1 AND CARCINOSARCOMA WALKER 256 EXPERIMENTALLY IN MICE AND RATS | 2020 |
|
RU2733643C1 |
METHOD OF SYNTHESIS 2-[3-(2-CHLORETHYL)-3-NITROSOUREIDO]-1,3-PROPANE-DIOL OWNED WITH ANTITUMOR ACTIVITY | 2018 |
|
RU2678846C1 |
USE OF THE COMPOUND 2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1,3-PROPANEDIOL IN TREATING MALIGNANT EYE SOCKET TUMOURS IN EXPERIMENT IN MICE WITH TRANSPLANTED INTRAORBITAL EHRLICH CARCINOMA | 2023 |
|
RU2815639C1 |
USE OF THE COMPOUND 2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1,3-PROPANEDIOL FOR TREATING HER2-POSITIVE TUMORS EXPERIMENTALLY | 2018 |
|
RU2695787C1 |
2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1,3-PROPANEDIOL SHOWING ANTITUMOR ACTIVITY | 1992 |
|
RU2068843C1 |
5-OXYMETHYL-5-[3-(2-CHLORETHYL)-3- NITROZOUREIDO]-2-CYCLOHEXYL- 1 | 2000 |
|
RU2179555C1 |
4(5)-(3-NITRO-4-(3,3-DIMETHYLTRIAZENO-1)PHENYL)IMIDAZOLE POSSESSING ANTITUMOR ACTIVITY | 1982 |
|
SU1074091A1 |
METHOD FOR CREATING POLYNEOPLASIA WITH STIMULATION OF TUMOR GROWTH IN CONDITIONS OF PRIMARY IMMUNODEFICIENCY IN EXPERIMENT | 2021 |
|
RU2751930C1 |
DIHYDROCHLORIDE 1-(3-NITRO-4- METHOXYBENZENE)-2- [BIS-(2- CHLORETHYL) AMINOMETHYL]IMIDAZOLE POSSESSING ANTITUMOR ACTIVITY | 1981 |
|
SU976654A1 |
METHOD OF MODIFYING THE DEVELOPMENT OF ADENOCARCINOMA EXPERIMENTALLY | 2020 |
|
RU2743960C1 |
Authors
Dates
2021-07-22—Published
2020-10-13—Filed